Ocera Therapeutics was founded in 2005 and is headquartered in Palo Alto, US

Ocera Therapeutics has offices in Palo Alto and Durham

Palo Alto, US (HQ)

610 525 University Ave

Durham, US

300 5001 S Miami Blvd

Ocera Therapeutics's revenue was reported to be $35 k in Q3, 2015

USD

## Net income (Q1, 2017) | (6.7 m) |

## Market capitalization (15-Aug-2017) | 27.7 m |

## Cash (31-Mar-2017) | 25.2 m |

Ocera Therapeutics's current market capitalization is $27.7 m.

USD | FY, 2016^{} |
---|---|

## R&D expense | 16.1 m |

## General and administrative expense | 10.4 m |

## Operating expense total | 26.5 m |

## Net Income | (26.9 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 33 k | 233 k | 31 k | 43 k | 35 k | ||||

## R&D expense | 4.8 m | 4.2 m | 4.4 m | 3.4 m | 4.2 m | 4.7 m | 3.9 m | 4.3 m | 3.9 m |

## General and administrative expense | 2.4 m | 2.7 m | 2.3 m | 2.8 m | 2.4 m | 2.6 m | 3 m | 2.6 m | 2.5 m |

## Operating expense total | 7.2 m | 6.9 m | 6.7 m | 6.2 m | 6.6 m | 7.3 m | 6.9 m | 6.9 m | 6.4 m |

## Net Income | (11.3 m) | (17.9 m) | (6.7 m) | (12.9 m) | (19.4 m) | (7.5 m) | (7.1 m) | (7.1 m) | (6.7 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 15.5 m | 10.1 m | 35.9 m | 24.6 m |

## Accounts Receivable | 93 k | 62 k | 59 k | |

## Inventories | 470 k | 970 k | 627 k | 584 k |

## Current Assets | 49.3 m | 48.3 m | 44 m | 28.9 m |

## PP&E | 59 k | 61 k | 94 k | 64 k |

## Goodwill | 595 k | 595 k | 595 k | 595 k |

## Total Assets | 51.8 m | 53.1 m | 44.7 m | 29.6 m |

## Accounts Payable | 1.3 m | 941 k | 701 k | 1.2 m |

## Total Debt | 19 m | |||

## Current Liabilities | 6.7 m | 2.9 m | 3.8 m | 13.8 m |

## Total Liabilities | 13.9 m | |||

## Additional Paid-in Capital | 126.6 m | 155.1 m | 162.8 m | 174.1 m |

## Retained Earnings | (104.9 m) | (131.4 m) | (158.3 m) | |

## Total Equity | 31.4 m | 15.7 m | ||

## Debt to Equity Ratio | 0.6 x | |||

## Debt to Assets Ratio | 0.4 x | |||

## Financial Leverage | 1.4 x | 1.9 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 12.5 m | 8.3 m | 10.3 m | 8.4 m | 22.8 m | 32.4 m | 34.2 m | 29.2 m | 25.2 m |

## Accounts Receivable | 33 k | 32 k | 31 k | 74 k | 35 k | 93 k | |||

## Current Assets | 44.5 m | 42 m | 48.6 m | 40.5 m | 35.9 m | 33.2 m | 25.9 m | ||

## PP&E | 75 k | 69 k | 53 k | 45 k | 109 k | 82 k | 69 k | 63 k | 54 k |

## Goodwill | 595 k | 595 k | 595 k | 595 k | 595 k | 595 k | 595 k | 595 k | 595 k |

## Total Assets | 39.8 m | 57.7 m | 47.5 m | 42.7 m | 49.4 m | 41.2 m | 36.6 m | 33.9 m | 26.6 m |

## Accounts Payable | 1.3 m | 1.1 m | 1 m | 1.1 m | 1 m | 1.3 m | 1.4 m | 2.1 m | 1.2 m |

## Current Liabilities | 3.3 m | 3 m | 3.5 m | 5 m | 6 m | 7.3 m | 13.1 m | ||

## Additional Paid-in Capital | 129.3 m | 154.1 m | 156 m | 157.4 m | 160.7 m | 165.7 m | 168 m | 172 m | 178.5 m |

## Retained Earnings | (92.8 m) | (99.4 m) | (111.6 m) | (117.8 m) | (124.4 m) | (138.9 m) | (146.1 m) | (153.2 m) | (165 m) |

## Total Equity | 36.5 m | 54.7 m | 44.5 m | 39.6 m | 36.4 m | 26.7 m | 21.9 m | 18.8 m | 13.5 m |

## Financial Leverage | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.4 x | 1.5 x | 1.7 x | 1.8 x | 2 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (17.5 m) | (23.4 m) | (26.5 m) | (26.9 m) |

## Depreciation and Amortization | 295 k | 164 k | 171 k | |

## Accounts Receivable | 45 k | 31 k | 3 k | |

## Accounts Payable | 14 k | (341 k) | (240 k) | 514 k |

## Cash From Operating Activities | (12 m) | (20.3 m) | (20.6 m) | (22.1 m) |

## Purchases of PP&E | (12 k) | (38 k) | (75 k) | (14 k) |

## Cash From Investing Activities | (21.3 m) | (8.9 m) | 33.2 m | 3.6 m |

## Cash From Financing Activities | 7.2 m | |||

## Interest Paid | 828 k |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (11.3 m) | (17.9 m) | (6.7 m) | (12.9 m) | (19.4 m) | (7.5 m) | (7.1 m) | (7.1 m) | (6.7 m) |

## Depreciation and Amortization | 102 k | 151 k | 49 k | 98 k | 146 k | 12 k | |||

## Accounts Receivable | 60 k | 61 k | 31 k | (12 k) | 27 k | (34 k) | |||

## Accounts Payable | 11 k | (239 k) | 88 k | 134 k | 73 k | 544 k | 1.4 m | 2.1 m | 1.2 m |

## Cash From Operating Activities | (10.4 m) | (16.1 m) | (4.9 m) | (10.1 m) | (15.1 m) | (5.2 m) | |||

## Purchases of PP&E | (23 k) | (38 k) | (71 k) | ||||||

## Cash From Investing Activities | 7 m | (14.9 m) | 5.1 m | 8 m | 15.5 m | (21 k) | |||

## Cash From Financing Activities | 1.8 m | ||||||||

## Interest Paid | 207 k |

Y, 2017 | |
---|---|

## Financial Leverage | 2 x |